Creative Medical Technology Holdings Inc (CELZ)

[UndervaludeOpportunity]

Actually, CELZ does have some revenue, but it’s still very early-stage and mostly R&D-focused. Their core pipeline is still in the clinical/preclinical phase, and the bulk of the story is based on future IP/licensing potential — not commercial operations yet.

If you’re looking for regenerative medicine plays that are already treating patients and generating real revenue, you might want to check out $RMTG.

They’ve got 26 clinics across 21 countries, are already profitable, and specialize in stem cell and peptide therapies being administered now — not 3 years from now.

I follow both, but they’re in completely different stages of development